These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18580955)

  • 21. [Comparative pharmacokinetic study of two different ways of using L-asparaginase as the main drug in combination chemotherapy].
    Wang Y; Jiang H; Xie X
    Zhonghua Xue Ye Xue Za Zhi; 1999 Nov; 20(11):589-91. PubMed ID: 11721378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance to glucocorticoids in childhood acute lymphoblastic leukemia: impact of relationship between ex vivo sensitivity and in vivo concentration on risk factor analysis.
    Styczynski J; Koltan A; Wysocki M
    Neoplasma; 2006; 53(2):168-73. PubMed ID: 16575474
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study.
    Avramis VI; Sencer S; Periclou AP; Sather H; Bostrom BC; Cohen LJ; Ettinger AG; Ettinger LJ; Franklin J; Gaynon PS; Hilden JM; Lange B; Majlessipour F; Mathew P; Needle M; Neglia J; Reaman G; Holcenberg JS; Stork L
    Blood; 2002 Mar; 99(6):1986-94. PubMed ID: 11877270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia.
    Ahlke E; Nowak-Göttl U; Schulze-Westhoff P; Werber G; Börste H; Würthwein G; Jürgens H; Boos J
    Br J Haematol; 1997 Mar; 96(4):675-81. PubMed ID: 9074406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase.
    Asselin BL; Ryan D; Frantz CN; Bernal SD; Leavitt P; Sallan SE; Cohen HJ
    Cancer Res; 1989 Aug; 49(15):4363-8. PubMed ID: 2743326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
    J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
    Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
    Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].
    Chen FX; Cui YQ; Wu ZL; Ye TZ; Lai YH; Zou YW; Lu CY; Guan JM; Wei FG; Zhang H
    Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):100-2. PubMed ID: 15921627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines.
    Ronghe M; Burke GA; Lowis SP; Estlin EJ
    Cancer Treat Rev; 2001 Dec; 27(6):327-37. PubMed ID: 11908926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
    Tong WH; Pieters R; Hop WC; Lanvers-Kaminsky C; Boos J; van der Sluis IM
    Pediatr Blood Cancer; 2013 Feb; 60(2):258-61. PubMed ID: 22961784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia.
    Thomas X; Archimbaud E; Charrin C; Magaud JP; Fiere D
    Leukemia; 1995 Feb; 9(2):249-53. PubMed ID: 7532767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review.
    Brigitha LJ; Pieters R; van der Sluis IM
    Eur J Cancer; 2021 Nov; 157():238-249. PubMed ID: 34536947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
    Hijiya N; Stewart CF; Zhou Y; Campana D; Coustan-Smith E; Rivera GK; Relling MV; Pui CH; Gajjar A
    Cancer; 2008 May; 112(9):1983-91. PubMed ID: 18318429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
    Earl M
    Clin Adv Hematol Oncol; 2009 Sep; 7(9):600-6. PubMed ID: 20020672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
    Panetta JC; Liu Y; Bottiglieri T; Arning E; Cheng C; Karol SE; Yang JJ; Zhou Y; Inaba H; Pui CH; Jeha S; Relling MV
    Cancer Chemother Pharmacol; 2021 Oct; 88(4):655-664. PubMed ID: 34170389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.
    Albertsen BK; Schrøder H; Jakobsen P; Avramis VI; Müller HJ; Schmiegelow K; Carlsen NT
    Med Pediatr Oncol; 2002 May; 38(5):310-6. PubMed ID: 11979454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erroneous exchange of asparaginase forms in the treatment of acute lymphoblastic leukemia.
    Cheung KC; van den Bemt PM; Torringa ML; Tamminga RY; Pieters R; de Smet PA
    J Pediatr Hematol Oncol; 2011 Apr; 33(3):e109-13. PubMed ID: 21368672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
    Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
    Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.
    Schlieben S; Borkhardt A; Reinisch I; Ritterbach J; Janssen JW; Ratei R; Schrappe M; Repp R; Zimmermann M; Kabisch H; Janka-Schaub G; Bartram CR; Ludwig WD; Riehm H; Lampert F; Harbott J
    Leukemia; 1996 Jun; 10(6):957-63. PubMed ID: 8667652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.